Alexion inks deal to acquire Achillion for $930M upfront
Alexion has struck a deal to buy Achillion for $930M. The takeover will give Alexion two clinical-phase medicines in development in complement alternative pathway-mediated rare diseases.
Achillion is focused on the development of oral small-molecule factor D inhibitors in indications such as paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy. Alexion has grown into a substantial business by treating complement-mediated diseases such as PNH and thinks there are enough differences in their approaches to make the acquisition of Achillion worthwhile.